Biogen revenue and financials
$221.39Change from previous close: −0.98%Absolute change: −$2.20
In the fiscal year ended December 2025, Biogen reported revenue of $9.89B (+2.22% year over year). Net income was $1.29B, a net margin of 13.1%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +2.22%
- 2025 vs 2024
- Net income growth
- −20.79%
- 2025 vs 2024
- Net margin
- 13.1%
- 2024: 16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2,205 | 2,876 | 1,547 | 1,384 | 3,640 | 4,230 | 7,079 | 6,188 | 4,551 | 4,587 |
| Depreciation and amortization | 780 | 673 | 495 | 518 | 488 | 457 | 465 | 651 | 1,081 | 683 |
| Capital expenditure | -154 | -154 | -277 | -240 | -258 | -425 | -515 | -771 | -867 | -616 |
| Investing cash flow | -1,371 | -799 | -4,101 | 1,577 | -564 | — | — | — | — | — |
| Financing cash flow | -302 | -684 | 149 | -1,747 | -2,086 | — | — | — | — | — |
| Share repurchases | — | 0.0 | 0.0 | -750 | -1,800 | -6,679 | -5,868 | -4,353 | -1,365 | -1,000 |
| Debt issued | 1,733 | 0.0 | 997 | 0.0 | — | — | — | — | — | — |
| Debt repaid | -1,750 | -650 | -810 | -1,002 | — | — | — | — | — | — |
| Effect of exchange rates | 102 | -67.7 | 35.1 | -55.7 | -59.8 | — | — | — | — | — |
| Net change in cash | 634 | 1,325 | -2,369 | 1,158 | 930 | — | — | — | — | — |
| Free cash flow | 2,051 | 2,722 | 1,270 | 1,144 | 3,382 | — | — | — | — | — |
| Levered free cash flow | 1,947 | 3,449 | 981 | 1,393 | 2,208 | — | — | — | — | — |